menu
    • menu
    [{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tagitanlimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Levena Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"A166","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Levena Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Levena Biopharma"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Levena Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"A166","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Sichuan Kelun-Biotech Biopharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Sichuan Kelun-Biotech Biopharmaceutical"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Sichuan Kelun-Biotech Biopharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Sichuan Kelun-Biotech Biopharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Sichuan Kelun-Biotech Biopharmaceutical

    Menu

    Sichuan Kelun-Biotech Biopharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            PharmScience R&D
                            Not Confirmed

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tagitanlimab,Cisplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kelun-Biotech's Tagitanlimab Approved for Second Indication in Recurrent NPC Treatment

                            Details : KL-A167 (tagitanlimab) is a PD-L1 inhibitor, is being investigated in combination with cisplatin and gemcitabine for the first-line treatment of recurrent or metastatic nasopharyngeal cancer (NPC).

                            Product Name : KL-A167

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 23, 2025

                            Lead Product(s) : Tagitanlimab,Cisplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            PharmScience R&D
                            Not Confirmed

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Tirumotecan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Breakthrough Designation to Sacituzumab for Advanced NSCLC with EGFR Mutations

                            Details : SKB264 (sacituzumab tirumotecan) is a TROP-2 targeting ADC, being investiated in adult with epidermal growth factor receptor (EGFR)-mutant locally advanced or metastatic non-small cell lung cancer.

                            Product Name : SKB264

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            December 03, 2024

                            Lead Product(s) : Sacituzumab Tirumotecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            PharmScience R&D
                            Not Confirmed

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Tirumotecan

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kelun-Biotech's Sacituzumab Tirumotecan Approved in China for Advanced TNBC

                            Details : Sac-TMT (sacituzumab tirumotecan) is a TROP2-directed antibody–drug conjugate which is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC.

                            Product Name : SKB264

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            November 27, 2024

                            Lead Product(s) : Sacituzumab Tirumotecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            PharmScience R&D
                            Not Confirmed

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Tirumotecan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kelun-Biotech’s SKB264 NDA Accepted for Advanced EGFR-Mutant NSCLC

                            Details : SKB264 (sacituzumab tirumotecan) is a TROP-2 targeting ADC, being investiated in adult with epidermal growth factor receptor (EGFR)-mutant locally advanced or metastatic non-small cell lung cancer.

                            Product Name : SKB264

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            October 31, 2024

                            Lead Product(s) : Sacituzumab Tirumotecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            PharmScience R&D
                            Not Confirmed

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Tirumotecan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kelun-Biotech's TROP2-ADC SKB264 NDA Accepted for Advanced NSCLC

                            Details : SKB264 (sacituzumab tirumotecan) is being evaluated in late-stage clinical trial studies with locally advanced or metastatic epidermal growth factor receptor-mutant non-small cell lung cancer.

                            Product Name : SKB264

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            August 20, 2024

                            Lead Product(s) : Sacituzumab Tirumotecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            PharmScience R&D
                            Not Confirmed

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : A166

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Levena Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Levena Biopharma, a Sorrento Company, are to Present Pos...

                            Details : A166 is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody conjugated to Duostatin-5, a novel anti-microtubule Auristatin derivative, via a proprietary stable covalent linker.

                            Product Name : A166

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            June 01, 2022

                            Lead Product(s) : A166

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Levena Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            PharmScience R&D
                            Not Confirmed

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : A166

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Levena Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candi...

                            Details : A166, a third-generation antibody-drug conjugate with tubulin inhibitor Duo-5 toxin, cleavable linker and site-specific K-Lock conjugation chemistry, demonstrated antitumor activity with meaningful responses in heavily pretreated subjects with HER2-posit...

                            Product Name : A166

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            May 03, 2022

                            Lead Product(s) : A166

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Levena Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth